Cell Source Inc. announced that they have received two patents for their Veto Cell Technology, which has been issued by the United States Patent and Trademark Office (USPTO). Veto Cell technology platform is based on a fundamental scientific discovery – the ability to use such veto T cells without the harmful ability of such T cells to induce Graft-versus-Host Disease (GvHD). Read more: https://bit.ly/3s7dxZu
